- Open Access
XPD suppresses cell proliferation and migration via miR-29a-3p-Mdm2/PDGF-B axis in HCC
© The Author(s) 2019
- Received: 20 November 2018
- Accepted: 31 December 2018
- Published: 5 January 2019
The aim of this study was to investigate the role of XPD in migration and invasion of hepatocellular carcinoma (HCC) cells.
The expression of XPD and miR-29a-3p was examined by western blot and qRT-PCR, cell proliferation was detected by MTT assay, cell migration was detected by transwell assay. TargetScan was used to predict potential targets of miR-29a-3p.
In this study, we found that the expression of XPD and miR-29a-3p was downregulated in HCC samples and HCC cell lines. XPD suppressed proliferation and migration of HCC cell via regulating miR-29a-3p expression. Target prediction analysis and dual-luciferase reporter assay confirmed Mdm2 and PDGF-B were direct targets of miR-29a-3p, and miR-29a-3p suppressed proliferation and migration of HCC cells via regulating the expression of Mdm2 or PDGF-B.
Our data indicated that XPD suppressed cell proliferation and migration via miR-29a-3p-Mdm2/PDGF-B axis in HCC.
- Cell proliferation and migration
- Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a primary neoplasm of the liver and the sixth most common solid tumor and the third most lethal malignancy globally . Since effectively diagnosing HCC at its early stage is particularly difficult, only 20% of HCC patients are amenable to curative therapy by liver transplant, surgical resection, or ablative therapy, and even then, some of these patients suffer from the recurring tumors [2, 3]. Moreover, HCC commonly recurs after curative therapy, with the prognosis for HCC patients with advanced-stage disease remaining rather poor . The need for novel therapeutic strategies is obvious and therefore, a better understanding of the underlying pathomechanisms is imperative.
Xeroderma pigmentosum D (XPD) is a subunit of transcription factor II H (TFIIH) , and involved in DNA unwinding during nucleotide excision repair (NER) . In order to allow the damaged-specific nucleases to cleave the damaged DNA, XPD unwinds the DNA around the damaged site via stimulation of 5′ → 3′ helicase activity . The liver is pivotal for many metabolic functions  and is very susceptible to carcinogenesis as the oxidant byproducts of hepatocellular metabolism often induced DNA damage. XPD has been reported to be down-regulated in patients with hepatocarcinoma . Emerging evidence indicates that XPD could prime cell cycle arrest, induce HCC apoptosis and inhibit its viability , which implicated that XPD may reverse the malignant phenotype of hepatoma cells by repairing the damaged DNA. Here, we further investigated the influence of XPD on hepatoma cell proliferation in the molecular mechanism perspective.
MicroRNAs (miRNAs), as a class of small noncoding RNA 19–25 nucleotide in length, take part in negatively regulation of gene expression. MiRNAs have an essential influence on many fundamentally important biological processes including cell apoptosis, differentiation, proliferation and metabolism . There is growing data have indicated that some tumor-specific miRNAs are widely downregulated or upregulated in HCC and closely associated with the occurrence and development of HCC [11, 12]. MiR-29a, currently one of the most interesting miRNA families in humans, has been shown to be silenced or downregulated in a wide range of cancers such as cell renal cell carcinoma , pediatric high-grade gliomas , in gastric cancer , including HCC .
We hypothesized that XPD might promote HCC cells migration and invasion through regulating the expression of miR-29a-3p. In this study, we first detected the expression of XPD and miR-29a-3p in tumor tissues from HCC patients. Furthermore, the underlying mechanism of XPD in the development of HCC was analyzed in vitro. This study might provide a better understanding of HCC pathogenesis and a potential therapeutic target for HCC intervention.
The study protocol was approved by the ethics committee of The Second Affiliated Hospital of Nanchang University, and all HCC patients provided written informed consents regarding the use of clinical specimens for the study.
Sample collection and cell culture
Sixty-eight HCC tissue samples were collected from patients who underwent hepatectomy as treatment of HCC at The Second Affiliated Hospital of Nanchang University. Information pertaining to the clinicopathological parameters was also available. Liver cancer cell lines (HepG2, SMMC-7721 and Hep3B) were purchased from American Type Culture Collection (ATCC, USA) and the normal human hepatic cell line (LO2) was preserved in our laboratory and maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) (Hyclone, USA), 100 U/ml of penicillin (Gibco, USA), and 100 μg/ml of streptomycin (Gibco, USA) at 5% CO2 and 37 °C. The medium was changed every 2 days, and cells were passaged at 70–80% confluence.
The XPD overexpression plasmid, vector, miR-29a-3p inhibitor, inhibitor negative control (NC), miR-29a-3p mimic, mimic NC, Mdm2 overexpression plasmid or PDGF-B overexpression plasmid transfected into SMMC7721 cell. XPD siRNA, scramble, miR-29a-3p mimic or mimic NC, miR-29a-3p inhibitor or inhibitor NC, Mdm2 siRNA or PDGF-B siRNA were synthesized by GenePharma (Shanghai, China) and transfected into Hep3B cell. All cell transfections were introduced by Lipofectamine 2000 (Invitrogen Life Technologies, USA) according to the manufacturer’s instructions. For each cell transfection, three replicates were performed.
Total proteins were extracted from Hep3B or SMMC-7721 cells using RIPA lysis buffer (Beyotime, China) and detected quantified with the BCA kit (Beyotime Biotechnology). Equal volume of protein were subjected to SDS-PAGE and transferred onto polyvinylidene difluoride membranes. After blocking in PBS with 5% skim milk for 1 h at room temperature, the membrane was incubated overnight at 4 °C with corresponding primary antibodies including XPD (1:1000; Abcam, Cambridge, UK), Mdm2 (1:100, Calbiochem, Bad Soden, Germany), P53 (1:400, Bioworld Technology Inc., Massachusetts, USA) and PDGF-B (1:1000; Abcam, Cambridge, UK), furthermore, it was incubated for 2 h with horseradish peroxidase (HRP) conjugated secondary antibodies at room temperature and the ECL kit was used to detect immunoreactive bands according to the manufacturer’s instructions (Thermo Scientific, Waltham, MA, USA).
Total RNA was extracted from the transfected cells and frozen tissues using TRIzol reagent (Invitrogen, USA) following the manufacturer’s protocol. Reverse transcription was carried out using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). cDNAs were subjected to real-time PCR with use of Power SYBR Green PCR Master Mix (Applied Biosystems) according to the manufacturer’s protocol. The results were calculated with the 2−△△Ct method.
Cell proliferation assay
The effect of XPD on SMMC7721 and Hep3B cell proliferation was measured by MTT assay. The cells were seeded in a 96-well plate at a density of 5000 monolayer cells per well. After 24 h, the cells were incubated with XPD for 24 h. Subsequently, the cells were washed with PBS and incubated with 20 µl MTT solution (5 g/l) for 4 h. After that, 150 µl DMSO (Shanghai Pharmaceutical Group, Shanghai, China) was added to each well to dissolve the crystals and then the plates were oscillated for 10 min in the dark. Finally, the optical density (OD) was measured at 490 nm using multifunctional fluorescence microplate reader. This experiment was performed in triplicate.
Cell migration assay
Cell migration was assessed by Transwell assays. Cells were suspended in 100 μl serum-free medium and were plated in the upper chamber of each insert (Corning, USA) with a Matrigel-coated membrane (BD Bioscience, San Jose, USA). The lower chambers of the inserts were filled with DMEM medium with 10% FBS. After 24 h of incubation, cells that migrated to the lower surface of the insert were fixed, stained with 20% methanol and 0.2% crystal violet, and counted under a light microscope (Olympus, Tokyo, Japan).
Luciferase reporter assay
Cells (5 × 104 cells/well) were cultured in a 24-well plate and co-transfected with wild type (Mdm2-WT, PDGF-B-WT) or mutant (Mdm2-Mut, PDGF-B-Mut), miR-29a-3p mimic and mimic NC using Lipofectamine 2000 (Invitrogen) for 48 h. Firefly activity was normalized to luciferase reporter plasmid (pRL-CMV). Renilla activity as control of transfection efficiency. The luciferase activities were measured by the dual-luciferase reporter assay system (Promega, Madison, WI) according to the manufacturer’s instructions.
All animal experiments were approved by the Ethical Committee on Animal Experiments at the The Second Affiliated Hospital of Nanchang University. For tumor growth assays, SMMC7721 cells treated with lentiviral vector of XPD overexpression, miR-29a-3p antagomiR, XPD overexpression + miR-29a-3p antagomiR or vehicle were subcutaneously injected into the right scapulas of nude mice (5-week-old BALB/c-nude, 8 per group, 2.0 × 106 cells for each mouse). The mice were observed over 34 days for tumor formation. The tumor volume was monitored every 3 days and calculated using the formula: V = 0.5 × length × width2.
All date were analyzed with SPSS 16.0. Data were presented as mean ± standard deviation (SD). Student’s t test was used to analyze differences between two groups. One-way ANOVA analysis was used to determine the multi-sample analysis. Differences at P < 0.05 were considered to be statistically significant.
The expressions of XPD and miR-29a-3p were downregulated in HCC
XPD suppressed proliferation and migration of HCC cell via regulating miR-29a-3p expression
MiR-29a-3p directly targeted Mdm2 or PDGF-B
MiR-29a-3p suppressed proliferation and migration of HCC cells via regulating the expression of Mdm2 or PDGF-B
XPD suppressed proliferation and migration of HCC cell via miR-29a-3p-Mdm2/PDGF-B axis
XPD suppressed cancer cell growth in vivo
XPD, a DNA helicase with 5′-3′ polarity, has been shown to be associated with a wide range of malignancies [17–19]. With specific respect to HCC, recent studies have tied XPD to increased HCC susceptibility [20, 21]. XPD expression serves as a tumor suppressor in HCC . To better understand XPD’s role in HCC, we investigated the in vitro cellular effects of XPD expression in HCC cells through transfection of the XPD gene into the HCC cell line SMMC7721 and Hep3B. We found that, relative to controls, XPD significantly inhibited HCC cell proliferation and migration. These combined findings indicate that XPD expression serves as a tumor suppressor in HCC cells in vitro, which is consistent with other previous in vitro studies on HCC cell lines . Previous studies have shown that miR-29a may act as a potential suppressor miRNA [24, 25]. For example, miR-29a was downregulated in cervical squamous cell carcinoma tissues and was correlated with its progression by inhibiting cervical cancer cell migration and invasion . In this study, we found that miR-29a-3p was positively correlated with XPD expression, and suppressed cell proliferation and migration of HCC cell lines, which in line with other works , moreover, the ability of miR-29a-3p to suppress cell proliferation and migration was markedly compromised when XPD expression was inhibited. These data indicated that XPD suppressed proliferation and migration of HCC cell via regulating miR-29a-3p expression, these results also implied that XPD might act as a tumor-suppressor whose downregulation contributed to the progression of HCC.
Tumor suppressor p53 plays a central role in preventing tumor formation. The levels and activity of p53 is under tight regulation to ensure its proper function. Murine double minute 2 (Mdm2), a p53 target gene, is an E3 ubiquitin ligase. Mdm2 is a key negative regulator of p53 protein, and forms an auto-regulatory feedback loop with p53 . Mdm2 often has increased expression levels in a variety of human cancers and promotes cancer cell proliferation [27–29]. In this study, we identified Mdm2 as a direct target gene of miR-29a-3p using bioinformatic prediction, dual-luciferase reporter assay and western blot. We also showed that the overexpression of miR-29a-3p inhibited Mdm2 protein expression and elevated P53 expression, we further validated that miR-29a-3p suppressed proliferation and migration of HCC cells via regulating the expression of Mdm2. P53 enhances Mdm2 transcription through p53 specific response elements in the promoter region of Mdm2, thus forming an auto-regulatory feedback loop, which is critical to control the balance of p53 and Mdm2 . MiR-29a is upregulated by p53, and miR-29a can successfully elevate the phosphorylation level of p53 by repression of Wip1, a phosphatase of p53 . Richard Moore et al.  revealed these feedback regulatory pathways are closely interlinked with the core p53-MDM2 autoregulation in that Wip1 upregulates MDM2 via inhibiting its degradation. Given that, we speculated XPD suppressed proliferation and migration of HCC cell via miR-29a-p53-MDM2 network. On the other hand, platelet-derived growth factor (PDGF)-B is critical signaling molecules which strongly promote multiple processes of tumorigenesis tumor progression, through stimulating angiogenesis and proliferation of tumor cells . Biological relevance of this signaling pathway has been demonstrated by therapeutic strategies targeting PDGF signaling and thereby inhibiting tumor growth . Previous study has shown that microRNA-363 suppresses the proliferation of hepatocellular carcinoma cells and the expression of PDGF-B was suppressed after miR-363 transfection . In this part of the study, we observed that the proliferation of HCC cells was slowed down by miR-29a-3p targeting PDGF-B. Our study may prompt a way to promote expression of miR-29a-3p and block MDM2/PDGF-B expression in HCC.
In conclusion, we demonstrated that XPD suppressed HCC cell proliferation and migration via regulating miR-29a-p53-MDM2/PDGF-B pathways, providing a new regulation mechanism of XPD expression in tumorigenesis. XPD-miR-29a-p53-MDM2/PDGF-B pathway may be a novel target for treatment of hepatocellular carcinoma.
ZX and HD conceived and designed the analysis. ZX, YW and HD collected the data. ZX, YW and HD contributed data or analysis tools. ZX, YW and HD performed the analysis. ZX and HD wrote the paper. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Consent for publication
Ethics approval and consent to participate
All procedures were approved by the Animal Care and Use Committee of The Second Affiliated Hospital of Nanchang University.
This study was funded by the National Natural Science Foundation of China (Grant No. 81300348).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and published work review. Hepatol Res. 2015;45(1):59–74. https://doi.org/10.1111/hepr.12378.View ArticlePubMedGoogle Scholar
- Schwabe RF, Wang TC. Targeting liver cancer: first steps toward a miRacle? Cancer Cell. 2011;20(6):698–9. https://doi.org/10.1016/j.ccr.2011.11.021.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang PR, Xu M, Toffanin S, Li Y, Llovet JM, Russell DW. Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci USA. 2012;109(28):11264–9. https://doi.org/10.1073/pnas.1117032109.View ArticlePubMedGoogle Scholar
- Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature. 1993;365(6449):852–5. https://doi.org/10.1038/365852a0.View ArticlePubMedGoogle Scholar
- Rudolf J, Rouillon C, Schwarz-Linek U, White MF. The helicase XPD unwinds bubble structures and is not stalled by DNA lesions removed by the nucleotide excision repair pathway. Nucleic Acids Res. 2010;38(3):931–41. https://doi.org/10.1093/nar/gkp1058.View ArticlePubMedGoogle Scholar
- Coin F, Marinoni JC, Rodolfo C, Fribourg S, Pedrini AM, Egly JM. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet. 1998;20(2):184–8. https://doi.org/10.1038/2491.View ArticlePubMedGoogle Scholar
- Askin DF, Diehl-Jones WL. The neonatal liver: part III: pathophysiology of liver dysfunction. Neonatal Netw NN. 2003;22(3):5–15. https://doi.org/10.1891/0730-08184.108.40.206.View ArticlePubMedGoogle Scholar
- Jaitovich-Groisman I, Benlimame N, Slagle BL, Perez MH, Alpert L, Song DJ, et al. Transcriptional regulation of the TFIIH transcription repair components XPB and XPD by the hepatitis B virus x protein in liver cells and transgenic liver tissue. J Biol Chem. 2001;276(17):14124–32. https://doi.org/10.1074/jbc.M010852200.View ArticlePubMedGoogle Scholar
- Wang HY, Xiong GF, Zhang JX, Xu H, Guo WH, Xu JJ, et al. The role of XPD in cell apoptosis and viability and its relationship with p53 and cdk2 in hepatoma cells. Med Oncol. 2012;29(1):161–7. https://doi.org/10.1007/s12032-011-9818-y.View ArticlePubMedGoogle Scholar
- Wang A, Landen NX, Meisgen F, Lohcharoenkal W, Stahle M, Sonkoly E, et al. MicroRNA-31 is overexpressed in cutaneous squamous cell carcinoma and regulates cell motility and colony formation ability of tumor cells. PLoS ONE. 2014;9(7):e103206. https://doi.org/10.1371/journal.pone.0103206.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhao X, Yang Z, Li G, Li D, Zhao Y, Wu Y, et al. The role and clinical implications of microRNAs in hepatocellular carcinoma. Sci China Life Sci. 2012;55(10):906–19. https://doi.org/10.1007/s11427-012-4384-x.View ArticlePubMedGoogle Scholar
- Chu R, Mo G, Duan Z, Huang M, Chang J, Li X, et al. miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression. Cell Commun Signal. 2014;12:45. https://doi.org/10.1186/s12964-014-0045-y.View ArticlePubMedPubMed CentralGoogle Scholar
- He H, Wang N, Yi X, Tang C, Wang D. Long non-coding RNA H19 regulates E2F1 expression by competitively sponging endogenous miR-29a-3p in clear cell renal cell carcinoma. Cell Biosci. 2017;7:65. https://doi.org/10.1186/s13578-017-0193-z.View ArticlePubMedPubMed CentralGoogle Scholar
- Catanzaro G, Sabato C, Russo M, Rosa A. Loss of miR-107, miR-181c and miR-29a-3p promote activation of Notch2 signaling in pediatric high-grade gliomas (pHGGs). Int J Mol Sci. 2017;18(12):2742. https://doi.org/10.3390/ijms18122742.View ArticlePubMed CentralGoogle Scholar
- Zhao Z, Wang L, Song W, Cui H, Chen G, Qiao F, et al. Reduced miR-29a-3p expression is linked to the cell proliferation and cell migration in gastric cancer. World J Surg Oncol. 2015;13:101. https://doi.org/10.1186/s12957-015-0513-x.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang X, Liu S, Cao L, Zhang T, Yue D, Wang L, et al. miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma. Oncotarget. 2017;8(49):86592–603. https://doi.org/10.18632/oncotarget.21246.View ArticlePubMedPubMed CentralGoogle Scholar
- Tengstrom M, Mannermaa A, Kosma VM, Soini Y, Hirvonen A, Kataja V. MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen. Acta Oncol. 2014;53(6):769–75. https://doi.org/10.3109/0284186x.2014.892210.View ArticlePubMedGoogle Scholar
- Avan A, Pacetti P, Reni M, Milella M, Vasile E, Mambrini A, et al. Prognostic factors in gemcitabine–cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int J Cancer. 2013;133(4):1016–22. https://doi.org/10.1002/ijc.28078.View ArticlePubMedGoogle Scholar
- Xue H, Lu Y, Lin B, Chen J, Tang F, Huang G. The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis. PLoS ONE. 2012;7(9):e43431. https://doi.org/10.1371/journal.pone.0043431.View ArticlePubMedPubMed CentralGoogle Scholar
- Guo LY, Jin XP, Niu W, Li XF, Liu BH, Wang YL. Association of XPD and XRCC1 genetic polymorphisms with hepatocellular carcinoma risk. Asian Pac J Cancer Prev APJCP. 2012;13(9):4423–6.View ArticleGoogle Scholar
- Yuan T, Deng S, Liu H, Liu M, Chen P. Relationship between XRCC1 and XPD polymorphisms and the risk of the development of hepatocellular carcinoma: a case–control study. Exp Ther Med. 2012;4(2):285–90. https://doi.org/10.3892/etm.2012.581.View ArticlePubMedPubMed CentralGoogle Scholar
- Zheng JF, Li LL, Lu J, Yan K, Guo WH, Zhang JX. XPD functions as a tumor suppressor and dysregulates autophagy in cultured HepG2 cells. Med Sci Monit Int Med J Exp Clin Res. 2015;21:1562–8. https://doi.org/10.12659/msm.894303.View ArticleGoogle Scholar
- Ding H, Xu JJ, Huang Y, Du FT, Zhang JX. XPD could suppress growth of HepG2.2.15 and down-regulate the expression of hepatitis B virus x protein through P53 pathway. Biochem Biophys Res Commun. 2012;419(4):761–7. https://doi.org/10.1016/j.bbrc.2012.02.097.View ArticlePubMedGoogle Scholar
- Yamamoto N, Kinoshita T, Nohata N, Yoshino H, Itesako T, Fujimura L, et al. Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma. Int J Oncol. 2013;43(6):1855–63. https://doi.org/10.3892/ijo.2013.2145.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen L, Xiao H, Wang ZH, Huang Y, Liu ZP, Ren H, et al. miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A. BMB Rep. 2014;47(1):39–44.View ArticleGoogle Scholar
- Zhao Y, Yu H, Hu W. The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin. 2014;46(3):180–9. https://doi.org/10.1093/abbs/gmt147.View ArticlePubMedGoogle Scholar
- Meng X, Franklin DA, Dong J, Zhang Y. MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res. 2014;74(24):7161–7. https://doi.org/10.1158/0008-5472.can-14-1446.View ArticlePubMedPubMed CentralGoogle Scholar
- Muthumani P, Alagarsamy K, Dhandayuthapani S, Venkatesan T, Rathinavelu A. Pro-angiogenic effects of MDM2 through HIF-1alpha and NF-kappaB mediated mechanisms in LNCaP prostate cancer cells. Mol Biol Rep. 2014;41(8):5533–41. https://doi.org/10.1007/s11033-014-3430-0.View ArticlePubMedGoogle Scholar
- Hai J, Sakashita S, Allo G, Ludkovski O, Ng C, Shepherd FA, et al. Inhibiting MDM2-p53 interaction suppresses tumor growth in patient-derived non-small cell lung cancer xenograft models. J Thorac Oncol. 2015;10(8):1172–80. https://doi.org/10.1097/jto.0000000000000584.View ArticlePubMedGoogle Scholar
- Ugalde AP, Ramsay AJ, de la Rosa J, Varela I, Marino G, Cadinanos J, et al. Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J. 2011;30(11):2219–32. https://doi.org/10.1038/emboj.2011.124.View ArticlePubMedPubMed CentralGoogle Scholar
- Moore R, Ooi HK, Kang T, Bleris L, Ma L. MiR-192-mediated positive feedback loop controls the robustness of stress-induced p53 oscillations in breast cancer cells. PLoS Comput Biol. 2015;11(12):e1004653. https://doi.org/10.1371/journal.pcbi.1004653.View ArticlePubMedPubMed CentralGoogle Scholar
- Usui S, Sugimoto N, Takuwa N, Sakagami S, Takata S, Kaneko S, et al. Blood lipid mediator sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression through S1P1-Gi-Ras-MAPK-dependent induction of Kruppel-like factor 5. J Biol Chem. 2004;279(13):12300–11. https://doi.org/10.1074/jbc.M305025200.View ArticlePubMedGoogle Scholar
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857.View ArticlePubMedGoogle Scholar
- Zhou P, Huang G, Zhao Y, Zhong D, Xu Z, Zeng Y, et al. MicroRNA-363-mediated downregulation of S1PR1 suppresses the proliferation of hepatocellular carcinoma cells. Cell Signal. 2014;26(6):1347–54. https://doi.org/10.1016/j.cellsig.2014.02.020.View ArticlePubMedGoogle Scholar